Multivariable regression for OS
| Characteristic . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Age (10-y increments) | 1.51 | 1.21-1.89 | <.001 |
| Clinical disease type (compared with de novo) | |||
| Secondary | 0.53 | 0.26-1.08 | .081 |
| Therapy-related | 2.49 | 0.69-8.99 | .2 |
| Relapsed disease (compared with refractory) | 0.70 | 0.38-1.30 | .3 |
| ≥2 prior lines of therapy | 1.65 | 0.86-3.17 | .13 |
| Prior FLT3 inhibitor | 0.87 | 0.49-1.55 | .6 |
| Low-intensity therapy in first line | 1.73 | 0.75-3.95 | .2 |
| Prior allogeneic transplant | 1.16 | 0.52-2.58 | .7 |
| Prior venetoclax | 1.22 | 0.55-2.71 | .6 |
| Normal karyotype | 1.53 | 0.63-3.72 | .3 |
| +8 | 0.60 | 0.17-2.11 | .4 |
| KMT2A rearrangement | 6.63 | 1.46-30.2 | .014 |
| MECOM rearrangement | 0.83 | 0.13-5.28 | .8 |
| Complex karyotype | 5.71 | 1.03-31.6 | .046 |
| Other adverse cytogenetic abnormality | 0.55 | 0.10-3.09 | .5 |
| FLT3-ITD | 0.66 | 0.07-6.27 | .7 |
| FLT3-TKD | 1.05 | 0.11-9.69 | >.9 |
| NPM1 mutation | 1.15 | 0.60-2.21 | .7 |
| DNMT3A mutation | 0.84 | 0.43-1.65 | .6 |
| ASXL1 mutation | 1.94 | 0.71-5.31 | .2 |
| RUNX1 mutation | 0.34 | 0.14-0.79 | .013 |
| SF3B1 mutation | 1.15 | 0.31-4.36 | .8 |
| SRSF2 mutation | 1.89 | 0.71-5.08 | .2 |
| IDH1/2 mutation | 1.39 | 0.67-2.90 | .4 |
| TET2 mutation | 1.17 | 0.52-2.63 | .7 |
| N/KRAS mutation | 0.55 | 0.18-1.69 | .3 |
| WT1 mutation | 0.99 | 0.35-2.84 | >.9 |
| Characteristic . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Age (10-y increments) | 1.51 | 1.21-1.89 | <.001 |
| Clinical disease type (compared with de novo) | |||
| Secondary | 0.53 | 0.26-1.08 | .081 |
| Therapy-related | 2.49 | 0.69-8.99 | .2 |
| Relapsed disease (compared with refractory) | 0.70 | 0.38-1.30 | .3 |
| ≥2 prior lines of therapy | 1.65 | 0.86-3.17 | .13 |
| Prior FLT3 inhibitor | 0.87 | 0.49-1.55 | .6 |
| Low-intensity therapy in first line | 1.73 | 0.75-3.95 | .2 |
| Prior allogeneic transplant | 1.16 | 0.52-2.58 | .7 |
| Prior venetoclax | 1.22 | 0.55-2.71 | .6 |
| Normal karyotype | 1.53 | 0.63-3.72 | .3 |
| +8 | 0.60 | 0.17-2.11 | .4 |
| KMT2A rearrangement | 6.63 | 1.46-30.2 | .014 |
| MECOM rearrangement | 0.83 | 0.13-5.28 | .8 |
| Complex karyotype | 5.71 | 1.03-31.6 | .046 |
| Other adverse cytogenetic abnormality | 0.55 | 0.10-3.09 | .5 |
| FLT3-ITD | 0.66 | 0.07-6.27 | .7 |
| FLT3-TKD | 1.05 | 0.11-9.69 | >.9 |
| NPM1 mutation | 1.15 | 0.60-2.21 | .7 |
| DNMT3A mutation | 0.84 | 0.43-1.65 | .6 |
| ASXL1 mutation | 1.94 | 0.71-5.31 | .2 |
| RUNX1 mutation | 0.34 | 0.14-0.79 | .013 |
| SF3B1 mutation | 1.15 | 0.31-4.36 | .8 |
| SRSF2 mutation | 1.89 | 0.71-5.08 | .2 |
| IDH1/2 mutation | 1.39 | 0.67-2.90 | .4 |
| TET2 mutation | 1.17 | 0.52-2.63 | .7 |
| N/KRAS mutation | 0.55 | 0.18-1.69 | .3 |
| WT1 mutation | 0.99 | 0.35-2.84 | >.9 |
Bold face denotes statistically significant variables